Infections after bispecific antibodies in B-cell lymphomas
Top Cited Papers
Open Access
- 13 March 2026
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (6) , 2006-2015
Abstract
Bispecific antibodies (BsAbs) have expanded therapeutic options for patients with relapsed/refractory B-cell lymphomas, yet their use has introduced a distinct spectrum of infectious complications that remain poorly characterized. In the largest cohort study to date, to our knowledge, we evaluated 109 patients treated with CD20×CD3 BsAbs between 2016 and 2024 to assess the incidence, characteristics, and risk factors of infections. Over a median follow-up of 28.4 months, 134 infectious episodes were identified, 61.2% of which were grade ≥3. The median time to infection onset was 6.6 months, with bacterial infections occurring earliest (5.9 months), followed by fungal (7.0 months) and viral infections (8.3 months). Among the microbiologically defined infections, viral infections were the most common (61.1%), with severe acute respiratory syndrome coronavirus 2 and cytomegalovirus (CMV) being the leading causes. Of the 109 patients, 68 (62.4%) experienced at least 1 infectious episode and 41 (37.6%) had grade ≥3 infections. The cumulative incidence of infection steadily increased over 24 months, reaching 76.4% at 24 months. The cumulative incidence of CMV infection steadily increased over the first 12 months. Neutropenia (absolute neutrophil count <1.0 × 109/L) and hypogammaglobulinemia (immunoglobulin G level <400 mg/dL) were independent risk factors for all-grade infection, whereas hypogammaglobulinemia was the sole independent risk factor for grade 3 to 5 infection. Early corticosteroid use was not associated with an increased infection risk. In summary, this study provides a temporal map of infection dynamics and highlights underrecognized complications, such as CMV reactivation. Risk-adapted therapeutic approaches and refined supportive care strategies are warranted for patients with B-cell lymphomas treated with BsAbs.Keywords
This publication has 46 references indexed in Scilit:
- Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell TransplantationNew England Journal of Medicine, 2017
- Cellular therapy for multiple pathogen infections after hematopoietic stem cell transplantCytotherapy, 2017
- Immune deficiency: changing spectrum of pathogensClinical and Experimental Immunology, 2015
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano ClassificationJournal of Clinical Oncology, 2014
- Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell TransplantationNew England Journal of Medicine, 2014
- Cytomegalovirus Infections in Solid Organ Transplantation: A ReviewInfection & Chemotherapy, 2013
- Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virusAnnals of Hematology, 2011
- Neutrophils in the activation and regulation of innate and adaptive immunityNature Reviews Immunology, 2011
- From the Immunocompromised Host Society: The Design, Analysis, and Reporting of Clinical Trials on the Empirical Antibiotic Management of the Neutropenic Patient: Report of a Consensus PanelThe Journal of Infectious Diseases, 1990
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987